Based on the evidence of subclinical myocardial damage produced by prediabetes (see Section 6.1, a recent article hypothesizes that sodium-glucose cotransporter-2 (SGLT-2) inhibitors administered in the prediabetic state might play a role in the prevention of heart failure (mainly HFpEF) in patients with diabetes mellitus [129]. This evidence concerns the gene SLC5A2 and diabetes mellitus.